Significant decrease in nelfinavir systemic exposure after omeprazole coadministration in healthy subjects

Pharmacotherapy

Volumn 28, Issue 1, 2008, Pages 42-50

  Fang, Annie F ^a,b   Damle, Bharat D ^a   LaBadie, Robert R ^a   Crownover, Penelope H ^a   Hewlett Jr , Dial ^a   Glue, Paul W ^a  

^a PFIZER INC   (United States)

^b M/S 685 2 14 ^*  (United States)

Author keywords

Drug drug interactions; Nelfinavir; Omeprazole; Pharmacokinetics; Protease inhibitors; Proton pump inhibitors

Indexed keywords

CYTOCHROME P450 2C19; CYTOCHROME P450 3A4; DRUG METABOLITE; NELFINAVIR; OMEPRAZOLE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; DIARRHEA; DIZZINESS; DRUG ELIMINATION; FEMALE; GASTROINTESTINAL SYMPTOM; HEADACHE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; NEUROLOGIC DISEASE; NORMAL HUMAN; OPEN STUDY; SYNCOPE; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADOLESCENT; ADULT; AREA UNDER CURVE; ARYL HYDROCARBON HYDROXYLASES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 CYP3A; DIARRHEA; DIZZINESS; DRUG INTERACTIONS; FEMALE; GASTRIC JUICE; HEADACHE; HIV PROTEASE INHIBITORS; HUMANS; HYDROGEN-ION CONCENTRATION; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; MIXED FUNCTION OXYGENASES; NELFINAVIR; OMEPRAZOLE; PROTON PUMP INHIBITORS; SYNCOPE; TABLETS;

EID: 38049092969     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.28.1.42     Document Type: Article

References (30)

1. Piacenti FJ. An update and review of antiretroviral therapy. Pharmacotherapy 2006;26:1111-33.
2. Young B. Mixing new cocktails: drug interactions in antiretroviral regimens. AIDS Patient Care STDS 2005;19: 286-97.
3. Perry CM, Frampton JE, McCormack PL, Siddiqui MSA, Cvetkoviç RS. Nelfinavir: a review of its use in the management of HIV infection. Drugs 2005;65:2209-44.
4. Bardsley-Elliot A, Plosker GL. Nelfinavir: an update on its use in HIV infection. Drugs 2000;59:581-620.
5. Zhang KE, Wu E, Patick AK, et al. Circulating metabolites of the human immunodeficiency virus protease inhibitor nelfinavir in humans: structural identification, levels in plasma, and antiviral activities. Antimicrob Agents Chemother 2001;45:1086-93.
6. Lillibridge JH, Lee CA, Pithavala YK, et al. The role of polymorphic CYP2C19 in the metabolism of nelfinavir mesylate. Presented at the 12th annual meeting of the American Association of Pharmaceutical Scientists, San Francisco, CA, November 15-19, 1998.
7. Hirani VN, Raucy JL, Lasker JM. Conversion of the HIV protease inhibitor nelfinavir to a bioactive metabolite by human liver CYP2C19. Drug Metab Dispos 2004;32:1462-7.
8. Anonymous. Physicians' Desk Reference, 52nd ed. Montvale, NJ: Medical Economics Group, Inc., 1998:528-32.
9. Andersson T. Pharmacokinetics, metabolism and interactions of acid pump inhibitors: focus on omeprazole, lansoprazole and pantoprazole. Clin Pharmacokinet 1996;31:9-28.
10. Ko JW, Sukhova N, Thacker D, Chen P, Flockhart DA. Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms. Drug Metab Dispos 1997;25: 853-62.
11. Burger DM, Hugen PW, Kroon FP, et al. A pharmacokinetic interaction between the proton pump inhibitor omeprazole and the HIV protease inhibitor indinavir. AIDS 1998;22:2080-2.
12. Tomilo DL, Smith PF, Ogundele AB, et al. Inhibition of atazanavir oral absorption by lansoprazole gastric acid suppression in healthy volunteers. Pharmacotherapy 2006;26:341-6.
13. Kiser JJ, Lichtenstein KA, Anderson PL, Fletcher CV. Effects of esomeprazole on the pharmacokinetics of atazanavir and fosamprenavir in a patient with human immunodeficiency virus infection. Pharmacotherapy 2006;26:511-14.
14. Food and Drug Administration. BMS Dear Dr. letter. Available from http://www.thebody.com/fda/pdfs/atazanavir_warning.pdf. Accessed September 10, 2005.
15. Bristol-Myers Squibb Co. Reyataz (atazanavir sulfate) package insert. Princeton, NJ; 2006.
16. Ford SL, Wire MB, Lou Y, Baker KL, Stein DS. Effect of antacids and ranitidine on the single-dose pharmacokinetics of fosamprenavir. Antimicrob Agents Chemother 2005;49:467-9.
17. El Shelton MJ, Ford SL, Borland J, et al. Coadministration of esomeprazole with fosamprenavir has no impact on steady-state plasma amprenavir pharmacokinetics. J Acquir Immune Defic Syndr 2006;42:61-7.
18. Winston A, Back D, Fletcher C, et al. Effect of omeprazole on the pharmacokinetics of saquinavir 500-mg formulation with ritonavir in healthy male and female volunteers. AIDS 2006;20:1401-6.
19. Boffito M, Carriero P, Trentini L, et al. Pharmacokinetics of saquinavir co-administered with cimetidine. J Antimicrob Chemother 2002;50:1081-4.
20. La Porte CJL. The effect of omeprazole, food and formulation on the pharmacokinetics of tipranavir coadministered with ritonavir (RTV). Presented at the 8th international workshop on clinical pharmacologv of HIV therapy, Budapest, Hungary, April 16-18, 2007.
21. Chiu YL, Klein CE, Woodward WC, et al. Lack of effect of gastric acid-reducing agents on the pharmacokinetics of lopinavir/ritonavir in HIV-infected patients. AIDS Patient Care STDS 2007;21:247-51.
22. Zhang KE, Wu E, Patick AK, et al. Circulating metabolites of the human immunodeficiency virus protease inhibitor nelfinavir in humans: structural identification, levels in plasma, and antiviral activities. Antimicrob Agents Chemother 2001;45:1086-93
23. Pfizer, Inc. Data on file. New York, NY; 1996.
24. Röhss K, Hasselgren G, Hedenström H. Effect of esomeprazole 40 mg vs omeprazole 40 mg on 24-hour intragastric pH in patients with symptoms of gastroesophageal reflux disease. Dig Dis Sci 2002;47:954-8.
25. Bowen WP, Carey JE, Miah A, et al. Measurement of cytochrome P450 gene induction in human hepatocytes using quantitative real-time reverse transcriptase-polymerase chain reaction. Drug Metab Dispos 2000;28:781-8.
26. Roymans D, Van Looveren C, Leone A, et al. Determination of cytochrome P450 1A2 and cytochrome P450 3A4 induction in cryopreserved human hepatocytes. Biochem Pharmacol 2004;67:427-37.
27. Raucy JL. Regulation of CYP3A4 expression in human hepatocytes by pharmaceuticals and natural products. Drug Metab Dispos 2003;31:533-9.
28. Krusekopf S, Roots I, Kleeberg U. Differential drug-induced mRNA expression of human CYP3A4 compared to CYP3A5, CYP3A7 and CYP3A43. Eur J Pharmacol 2003;11:7-12.
29. Lemahieu WP, Maes BD, Verbeke K, Vanrenterghem Y. Impact of gastric acid suppressants on cytochrome P450 3A4 and P-glycoprotein: consequences for FK506 assimilation. Kidney Int 2005;67:1152-60.
30. Lindell M, Karlsson MO, Lennernäs H, Påhlman L, Lang MA. Variable expression of CYP and Pgp genes in the human small intestine. Eur J Clin Invest 2003;33:493-9.